[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT92278A - Processo para a preparacao de proteinas de ligacao de factor de crescimento semelhante a insulina - Google Patents

Processo para a preparacao de proteinas de ligacao de factor de crescimento semelhante a insulina

Info

Publication number
PT92278A
PT92278A PT92278A PT9227889A PT92278A PT 92278 A PT92278 A PT 92278A PT 92278 A PT92278 A PT 92278A PT 9227889 A PT9227889 A PT 9227889A PT 92278 A PT92278 A PT 92278A
Authority
PT
Portugal
Prior art keywords
proteins
ligaction
growth factor
preparing insulin
insulin
Prior art date
Application number
PT92278A
Other languages
English (en)
Other versions
PT92278B (pt
Inventor
Christopher Binkert
Guenther F Heinrich
Jurg Schwander
Original Assignee
Sandoz Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Sa filed Critical Sandoz Sa
Publication of PT92278A publication Critical patent/PT92278A/pt
Publication of PT92278B publication Critical patent/PT92278B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT92278A 1988-11-11 1989-11-10 Processo para a preparacao de proteinas de ligacao de factor de crescimento semelhante a insulina PT92278B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888826451A GB8826451D0 (en) 1988-11-11 1988-11-11 Improvements in/relating to organic compounds

Publications (2)

Publication Number Publication Date
PT92278A true PT92278A (pt) 1990-05-31
PT92278B PT92278B (pt) 1995-09-12

Family

ID=10646720

Family Applications (1)

Application Number Title Priority Date Filing Date
PT92278A PT92278B (pt) 1988-11-11 1989-11-10 Processo para a preparacao de proteinas de ligacao de factor de crescimento semelhante a insulina

Country Status (16)

Country Link
EP (1) EP0369943B1 (pt)
JP (1) JPH0341096A (pt)
AT (1) ATE112311T1 (pt)
AU (1) AU623447B2 (pt)
CA (1) CA2002609A1 (pt)
DE (1) DE68918556D1 (pt)
DK (1) DK564989A (pt)
FI (1) FI895346A0 (pt)
GB (1) GB8826451D0 (pt)
HU (2) HU895607D0 (pt)
IL (1) IL92257A0 (pt)
MY (1) MY104673A (pt)
NZ (1) NZ231333A (pt)
PL (1) PL162290B1 (pt)
PT (1) PT92278B (pt)
ZA (1) ZA898610B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5212074A (en) * 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
EP0546081A4 (en) * 1990-08-28 1994-08-17 Chiron Corp New insulin-like growth factor binding protein (igfbp-4)
EP0546074B1 (en) * 1990-08-28 2001-11-14 Chiron Corporation Genetic material encoding igfbp-5
US6326154B1 (en) 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
EP0556344B1 (en) * 1991-01-08 2003-08-13 Chiron Corporation New insulin-like growth factor binding protein
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
AU6626794A (en) * 1993-04-07 1994-10-24 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins
JPH09507832A (ja) * 1993-09-20 1997-08-12 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆｂｐ単独またはｉｇｆｂｐとｉｇｆとの複合体による免疫疾患および血液疾患の処置
SE9303784D0 (sv) * 1993-11-16 1993-11-16 Kabi Pharmacia Ab Igf
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
IL143834A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
AU2002248609B2 (en) 2001-03-14 2007-03-01 Genentech, Inc. IGF antagonist peptides
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
NZ545940A (en) 2003-09-12 2009-12-24 Tercica Inc Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
EP1670822A2 (en) 2003-10-03 2006-06-21 Genentech, Inc. Igf binding proteins
DK2100614T3 (da) 2005-06-17 2013-10-28 Imclone Llc Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
WO2007092453A2 (en) 2006-02-03 2007-08-16 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
PE20201166A1 (es) 2017-09-11 2020-10-28 Shire Human Genetic Therapies Metodos y composiciones para tratar enfermedades pulmonares cronicas
KR20230113287A (ko) 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물
MX2024008819A (es) 2022-01-19 2024-09-17 Oak Hill Bio Ltd Composiciones y metodos para reducir la oxidacion de igf-1/igfbp.
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2024170612A1 (en) 2023-02-14 2024-08-22 Oak Hill Bio Limited Treatment of healing dysregulation in gi tissue

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
EP0418230B1 (en) * 1988-04-12 1995-12-27 Amgen Boulder Inc. Method for potentiating and inhibiting insulin-like growth factor activity

Also Published As

Publication number Publication date
MY104673A (en) 1994-05-31
HUT53936A (en) 1990-12-28
AU4453689A (en) 1990-06-07
ZA898610B (en) 1991-07-31
DK564989A (da) 1990-05-12
DE68918556D1 (de) 1994-11-03
HU895836D0 (en) 1990-01-28
DK564989D0 (da) 1989-11-10
PT92278B (pt) 1995-09-12
JPH0341096A (ja) 1991-02-21
NZ231333A (en) 1992-10-28
EP0369943B1 (en) 1994-09-28
FI895346A0 (fi) 1989-11-09
PL162290B1 (pl) 1993-09-30
ATE112311T1 (de) 1994-10-15
GB8826451D0 (en) 1988-12-14
EP0369943A1 (en) 1990-05-23
CA2002609A1 (en) 1990-05-11
HU895607D0 (en) 1990-01-28
AU623447B2 (en) 1992-05-14
IL92257A0 (en) 1990-07-26

Similar Documents

Publication Publication Date Title
PT92278A (pt) Processo para a preparacao de proteinas de ligacao de factor de crescimento semelhante a insulina
DE68902375D1 (de) Verfahren zur vorsulfidierung von kohlenwasserstoffbehandlungskatalysatoren.
DE69021263D1 (de) Fibronektinbindungsprotein und dessen Herstellung.
HUT40165A (en) Process for preparing dog and horse interferones
ES2058341T3 (es) Subunidades de proteina portadoras de somatomedina humana y proceso para producirlas.
PT93128A (pt) Processo para a preparacao de um concentrado de factor de von willebrand purificado e pasteurizado
DE3667340D1 (de) Verfahren zur herstellung von steuermatrixen mit dioden fuer elektrooptische anzeigeschirmplatte und nach diesem verfahren hergestellte schirmplatte.
ATE117985T1 (de) Verfahren mit hoher energieleistung zur herstellung von harnstoff.
PT92603A (pt) Processo de producao de factor de crescimento transformante, quimerico,beta
DE3781564D1 (de) Verfahren zur herstellung von bromierten pyrrolo-(3,4-c)-pyrrolen.
DE3769164D1 (de) Verfahren zur herstellung von flaechigem halbzeug.
DE68906500D1 (de) Verfahren zur herstellung von 2,6-dimethylnaphthalin.
DE68905729D1 (de) Kontinuierliches verfahren zur herstellung von dichlorhydrin.
DE3581216D1 (de) Verfahren zur herstellung von propanol.
AT364813B (de) Verfahren zur herstellung von alpha-aryl-alpha, alpha-di(omega-aminoalkyl)acetamiden mit disubstituierter aminogruppe
DE68907180D1 (de) Verfahren zur herstellung von 2,3,5-trimethylbenzochinon.
DE68904457D1 (de) Verfahren zur herstellung von alkandiolen.
ATE190653T1 (de) Verfahren zur herstellung von rekombinanten und synthetischen peptiden und deren verwendung
DE68901576D1 (de) Verfahren zur herstellung von 2,3,5-trimethylbenzochinon.
DE58904614D1 (de) Verfahren zur herstellung von 1,1,2-trialkoxyethanen.
DE59002140D1 (de) Verfahren zur herstellung von 2,3,5-trimethyl-p-benzochinon.
DE69018261D1 (de) Verbessertes verfahren zur herstellung von 1,2,4-triazol-5-on mit niedrigem chlorgehalt.
DE58903809D1 (de) Verfahren zur herstellung von 4,4'-dinitrodiphenylamin.
DE68901736D1 (de) Verfahren zur herstellung von alkandiolen.
DE68906465D1 (de) Verfahren zur herstellung von 2,3-dimethoxy-5-methylbenzochinon.

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19950503

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19961130